Arthrosamid: official partner
An inspiring new commercial partnership which will see key messages about the benefits of non-surgical alternatives for the treatment of pain associated with knee osteoarthritis (OA) disseminated across grassroots clubs and RunTogether groups.
Arthrosamid, Contura Orthopaedics and England Athletics are announcing the launch of an inspiring new commercial partnership which will see key messages about the benefits of non-surgical alternatives for the treatment of pain associated with knee osteoarthritis (OA) disseminated across a affiliated grassroots clubs and RunTogether groups.
The collaboration will include workshops, webinars and in-person events, as well as the recruitment of a new panel of Ambassadors and will shine a light on the importance of emerging innovation in the osteoarthritis ‘space’, whilst raising awareness of treatment options designed to maintain mobility – and crucially, to help keep people running!
An insightful new survey conducted by England Athletics* as part of this project revealed that almost 9 in 10 of the athletes questioned claimed to have experienced knee pain which prevented them from running, with the majority acting in the form of rest (88%) painkillers (64%) or physiotherapy (63%). And, over half (51%) of those asked admitted they would consider paying for treatment for knee pain if it meant avoiding surgery.
And, as such, Arthrosamid®, has been hailed by clinicians as an exciting game changer: the first and only injectable hydrogel proven to help patients with knee osteoarthritis, offering a real alternative to surgery.
*England Athletics knee injury survey, Nov 2024, N=131
Eligible patients receive a single injection into the knee joint space which permanently combines with the knee’s synovial tissue – decreasing joint stiffness, diminishing pain, improving the function of the knee affected by knee osteoarthritis, and enhancing quality of life.
Encouragingly, new four-year data presented in September 2024 at the European Orthopaedic Research Society Meeting (EORS) in Aalborg, Denmark demonstrated the long-term efficacy of the hydrogel injection – showing that a single dose maintained a statistically significant reduction in pain in patients with knee OA four years after treatment.**
**Bliddal, H., et al. (2024) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 4 Years After Treatment. Presented at EORS 2024.
Note: To receive offers via our eComms, you should log into My RunTogether and ensure your communications preferences are set to YES. eComms are usually sent monthly.